<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>382</serviceExecutionTime><Drug id="16917"><DrugName>nitroglycerin ointment</DrugName><DrugNamesKey><Name id="42973378">Anogesic</Name><Name id="42973379">Cellegesic</Name><Name id="42973381">Rectiv</Name><Name id="42973380">Rectogesic</Name><Name id="43059777">Ruituoxi</Name><Name id="42750099">nitroglycerin</Name></DrugNamesKey><DrugSynonyms><Name><Value>nitroglycerin</Value><Types><Type>USAN</Type></Types></Name><Name><Value>nitroglycerin ointment</Value></Name><Name><Value>Anogesic</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Cellegesic</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Rectogesic</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Rectiv</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ruituoxi</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>55-63-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23168">Neptune Pharmaceutical Corp</CompanyOriginator><CompaniesPrimary><Company id="27477">Paladin Labs Inc</Company><Company id="1010792">Kyowa Kirin</Company><Company id="22872">Aptalis Pharma Inc</Company><Company id="22209">Adamis Pharmaceuticals Corp</Company><Company id="27664">Orexo AB</Company><Company id="1043484">Epsilon Pharmaceuticals</Company></CompaniesPrimary><CompaniesSecondary><Company id="23168">Neptune Pharmaceutical Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16917" type="Drug"><TargetEntity id="91426" type="siDrug">Nitroglycerin</TargetEntity></SourceEntity><SourceEntity id="1010792" type="Company"><TargetEntity id="4295897870" type="organizationId">Kyowa Kirin International PLC</TargetEntity></SourceEntity><SourceEntity id="1043484" type="Company"><TargetEntity id="4296173643" type="organizationId">Epsilon Pharmaceuticals Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="22209" type="Company"><TargetEntity id="4295905898" type="organizationId">Adamis Pharmaceuticals Corp</TargetEntity></SourceEntity><SourceEntity id="22872" type="Company"><TargetEntity id="5037100987" type="organizationId">Aptalis Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="23168" type="Company"><TargetEntity id="5035554786" type="organizationId">Neptune Pharmaceutical Corp</TargetEntity></SourceEntity><SourceEntity id="27477" type="Company"><TargetEntity id="4295862339" type="organizationId">Paladin Labs Inc</TargetEntity></SourceEntity><SourceEntity id="27664" type="Company"><TargetEntity id="4295890191" type="organizationId">Orexo AB</TargetEntity></SourceEntity><SourceEntity id="1276" type="ciIndication"><TargetEntity id="10057671" type="MEDDRA"></TargetEntity><TargetEntity id="572" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="147" type="ciIndication"><TargetEntity id="455" type="ICD9"></TargetEntity><TargetEntity id="10019022" type="MEDDRA"></TargetEntity><TargetEntity id="D006484" type="MeSH"></TargetEntity><TargetEntity id="-985895683" type="omicsDisease"></TargetEntity><TargetEntity id="372" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2694" type="ciIndication"><TargetEntity id="N94.1" type="ICD10"></TargetEntity><TargetEntity id="10013941" type="MEDDRA"></TargetEntity><TargetEntity id="D004414" type="MeSH"></TargetEntity><TargetEntity id="-770117628" type="omicsDisease"></TargetEntity><TargetEntity id="3303" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3648" type="ciIndication"><TargetEntity id="10036772" type="MEDDRA"></TargetEntity><TargetEntity id="4508" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anus pain - Australia - Jun-2000</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="3648">Anus pain</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1276">Female sexual dysfunction</Indication><Indication id="147">Hemorrhoids</Indication><Indication id="2694">Dyspareunia</Indication></IndicationsSecondary><ActionsSecondary><Action id="277">NO receptor agonist</Action><Action id="388">Vasodilator</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="612">Emulsion dermatological</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="558">Transdermal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="767">Rectal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-29T10:13:25.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>1998-01-09T11:39:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed by  &lt;ulink linkID="22209" linkType="Company"&gt;Cellegy&lt;/ulink&gt; (now &lt;ulink linkID="22209" linkType="Company"&gt;Adamis Pharmaceuticals&lt;/ulink&gt;), under license from &lt;ulink linkID="23168" linkType="Company"&gt;Neptune&lt;/ulink&gt;, and now marketed by multiple licensees including &lt;ulink linkID="1010792" linkType="Company"&gt;Kyowa Kirin&lt;/ulink&gt; (formerly ProStrakan; now a subsidiary of &lt;ulink linkID="1042596" linkType="Company"&gt;Kyowa Hakko Kirin&lt;/ulink&gt;) and &lt;ulink linkID="22872" linkType="Company"&gt;Aptalis&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="16198" linkType="Company"&gt;Forest Laboratories&lt;/ulink&gt; (formerly &lt;ulink linkID="1088700" linkType="Company"&gt;Actavis&lt;/ulink&gt;; now &lt;ulink linkID="1088700" linkType="Company"&gt;Allergan&lt;/ulink&gt;)), Rectiv (Cellegesic; known as Rectogesic (formerly Anogesic) outside  the US) is a 0.4% nitroglycerin ointment  indicated in the US for the  treatment of moderate to severe pain associated with chronic anal fissure, and in the EU for relief of pain associated with chronic anal fissure [&lt;ulink linkID="1463095" linkType="Reference"&gt;1463095&lt;/ulink&gt;], [&lt;ulink linkID="1463106" linkType="Reference"&gt;1463106&lt;/ulink&gt;], [&lt;ulink linkID="1520770" linkType="Reference"&gt;1520770&lt;/ulink&gt;], [&lt;ulink linkID="1574106" linkType="Reference"&gt;1574106&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The product was first launched in Australia by &lt;ulink linkID="28905" linkType="Company"&gt;Quay&lt;/ulink&gt;  (acquired by Cellegy) in 3Q99 [&lt;ulink linkID="371267" linkType="Reference"&gt;371267&lt;/ulink&gt;]. In May 2005, it was launched in the UK [&lt;ulink linkID="604479" linkType="Reference"&gt;604479&lt;/ulink&gt;], and subsequently in other EU countries   [&lt;ulink linkID="829938" linkType="Reference"&gt;829938&lt;/ulink&gt;],   [&lt;ulink linkID="1458617" linkType="Reference"&gt;1458617&lt;/ulink&gt;], [&lt;ulink linkID="1386594" linkType="Reference"&gt;1386594&lt;/ulink&gt;]. In March 2012, Aptalis started promoting the product as Rectiv in the US [&lt;ulink linkID="1272428" linkType="Reference"&gt;1272428&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Cellegy was previously developing the drug for female sexual dysfunction, dyspareunia and hemorrhoids [&lt;ulink linkID="426980" linkType="Reference"&gt;426980&lt;/ulink&gt;], [&lt;ulink linkID="462213" linkType="Reference"&gt;462213&lt;/ulink&gt;]. By October 2004, a phase I/II trial for dyspareunia was underway [&lt;ulink linkID="563590" linkType="Reference"&gt;563590&lt;/ulink&gt;]. In March 2005, clinical data were reported from a study for symptomatic chronic hemorrhoids [&lt;ulink linkID="591820" linkType="Reference"&gt;591820&lt;/ulink&gt;]. However, no further development has since been reported and development for these indications is presumed to have been discontinued.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Cellegesic is protected by two broad US patents obtained in 1997. By January 1998, a number of patents had also been filed outside the US [&lt;ulink linkID="274032" linkType="reference"&gt;274032&lt;/ulink&gt;]. &lt;ulink linkID="PA2967334" linkType="Patent"&gt;US-07189761&lt;/ulink&gt;, preventing generic competition, expired in May 2014. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2000, Cellegy was granted &lt;ulink linkID="IN2276476" linkType="Patent"&gt;EP-00719145&lt;/ulink&gt;B, covering the manufacture and use of nitroglycerin ointment and related compounds for the treatment of anal disorders, including anal fissures and various hemorrhoidal conditions. Patent applications were pending in other international markets at this time [&lt;ulink linkID="382105" linkType="reference"&gt;382105&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2001, Cellegy announced that two oppositions have been filed with the EPO regarding EP-0719145B1 [&lt;ulink linkID="412856" linkType="reference"&gt;412856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;A Chinese patent that would expire in April 2015 covered the product [&lt;ulink linkID="636646" linkType="Reference"&gt;636646&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In January 2001, the Canadian Intellectual Property Office granted Cellegy patent &lt;ulink linkID="IN2219520" linkType="Patent"&gt;CA-02168247&lt;/ulink&gt; (which is equivalent to &lt;ulink linkID="IN2197281" linkType="Patent"&gt;WO-09532715&lt;/ulink&gt; granted to Neptune), covering compositions useful in treating anal disorders including anal fissures with nitroglycerin (Cellegesic) and other related compounds [&lt;ulink linkID="394937" linkType="reference"&gt;394937&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2001, Cellegy filed an NDA with the FDA requesting review of existing data for the treatment of pain associated with chronic anal fissures [&lt;ulink linkID="413649" linkType="reference"&gt;413649&lt;/ulink&gt;]. In December 2001, Cellegy submitted a supplement to the NDA to include data from its completed confirmatory phase III study [&lt;ulink linkID="425153" linkType="reference"&gt;425153&lt;/ulink&gt;], [&lt;ulink linkID="432131" linkType="reference"&gt;432131&lt;/ulink&gt;]. In January 2002, the company expected FDA approval by mid-2002  [&lt;ulink linkID="437621" linkType="reference"&gt;437621&lt;/ulink&gt;], [&lt;ulink linkID="449604" linkType="reference"&gt;449604&lt;/ulink&gt;]. However, in April 2002, Cellegy withdrew its NDA after the FDA stated additional information was required for approval [&lt;ulink linkID="449575" linkType="reference"&gt;449575&lt;/ulink&gt;]. Cellegy met with the FDA in June 2002 to agree on supplemental analyses required [&lt;ulink linkID="455018" linkType="reference"&gt;455018&lt;/ulink&gt;]; in September 2002, Cellegy reported that the FDA required an additional phase III trial   [&lt;ulink linkID="463347" linkType="reference"&gt;463347&lt;/ulink&gt;]. This study began in June 2003 [&lt;ulink linkID="500241" linkType="reference"&gt;500241&lt;/ulink&gt;], and in January 2004, the trial was complete [&lt;ulink linkID="518599" linkType="reference"&gt;518599&lt;/ulink&gt;]. The NDA was refiled in June 2004 [&lt;ulink linkID="546929" linkType="reference"&gt;546929&lt;/ulink&gt;] and accepted for review in September 2004 [&lt;ulink linkID="557103" linkType="Reference"&gt;557103&lt;/ulink&gt;]. In October 2004, Priority Review status was granted  [&lt;ulink linkID="564500" linkType="Reference"&gt;564500&lt;/ulink&gt;]. In December 2004, the FDA issued a non-approvable letter for Cellegesic [&lt;ulink linkID="577582" linkType="Reference"&gt;577582&lt;/ulink&gt;]. In April 2005, following discussions with the FDA, Cellegy submitted a written response, which it stated addressed all the issues raised [&lt;ulink linkID="595656" linkType="Reference"&gt;595656&lt;/ulink&gt;]. In May 2005, the FDA was reviewing the amended NDA [&lt;ulink linkID="599630" linkType="Reference"&gt;599630&lt;/ulink&gt;]. In November 2005, the company announced that the FDA's Cardio-Renal Advisory Committee would review the application  [&lt;ulink linkID="644258" linkType="Reference"&gt;644258&lt;/ulink&gt;]; in April 2006, the committee was split 50:50 in recommending  approval of the drug  or approval pending the result of an extra efficacy study [&lt;ulink linkID="663909" linkType="Reference"&gt;663909&lt;/ulink&gt;]. In July 2006, the FDA issued an approvable letter requesting a further clinical trial. The agency said the company's completed clinical trials did not provide enough evidence that the drug was effective. Cellegy planned to meet with the agency to discuss its options [&lt;ulink linkID="677601" linkType="Reference"&gt;677601&lt;/ulink&gt;]. In July 2007, the FDA approved the trial design and development [&lt;ulink linkID="811092" linkType="Reference"&gt;811092&lt;/ulink&gt;]. In October 2009, the FDA accepted for review a refiling of the NDA for pain associated with chronic anal fissures [&lt;ulink linkID="1051015" linkType="Reference"&gt;1051015&lt;/ulink&gt;].  In April 2010, the FDA issued a Complete Response requesting additional information, including additional clinical data. Kyowa Kirin indended to meet with the FDA to discuss the details further [&lt;ulink linkID="1087030" linkType="Reference"&gt;1087030&lt;/ulink&gt;]. In December 2010, the NDA was refiled [&lt;ulink linkID="1159883" linkType="Reference"&gt;1159883&lt;/ulink&gt;]. In June 2011, the FDA approved the drug, as Rectiv, for  moderate to severe pain associated with chronic anal fissures [&lt;ulink linkID="1202314" linkType="Reference"&gt;1202314&lt;/ulink&gt;]; the product was launched by partner Aptalis in March 2012 [&lt;ulink linkID="1272428" linkType="Reference"&gt;1272428&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2001, Cellegy filed for UK approval; the UK was to act as the reference member state for EU approval [&lt;ulink linkID="421078" linkType="Reference"&gt;421078&lt;/ulink&gt;]. In July 2004, the UK's Committee on Safety of Medicines recommended approval [&lt;ulink linkID="547933" linkType="reference"&gt;547933&lt;/ulink&gt;]. UK approval was granted in September 2004 [&lt;ulink linkID="558818" linkType="Reference"&gt;558818&lt;/ulink&gt;], ad the product was launched in the UK in May 2005 [&lt;ulink linkID="604479" linkType="Reference"&gt;604479&lt;/ulink&gt;]. By November 2005, further European approvals were being sought under the MRP [&lt;ulink linkID="633154" linkType="Reference"&gt;633154&lt;/ulink&gt;]. In March 2006, Kyowa Kirin announced the successful completion of the MRP for Cellegesic. National licenses in the 19 additional countries included in the MRP submission  would be issued in due course [&lt;ulink linkID="657685" linkType="Reference"&gt;657685&lt;/ulink&gt;]. In February 2007, the drug was launched in Sweden [&lt;ulink linkID="1412517" linkType="Reference"&gt;1412517&lt;/ulink&gt;]. In June 2007, the drug was launched as  Rectogesic in France [&lt;ulink linkID="1351447" linkType="Reference"&gt;1351447&lt;/ulink&gt;]. By July 2007, the drug had been  launched in Germany   [&lt;ulink linkID="811092" linkType="Reference"&gt;811092&lt;/ulink&gt;].  In November 2007, the drug was launched in Norway [&lt;ulink linkID="1458617" linkType="Reference"&gt;1458617&lt;/ulink&gt;]. In June 2008, Rectogesic was launched in Portugal [&lt;ulink linkID="1386594" linkType="Reference"&gt;1386594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In March 2002, Cellegy filed for approval in Canada [&lt;ulink linkID="444619" linkType="Reference"&gt;444619&lt;/ulink&gt;]; however, since that time no further development was reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By May 2010, the drug had been launched in Israel [&lt;ulink linkID="1100921" linkType="Reference"&gt;1100921&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;Cellegesic was launched by &lt;ulink linkID="1022100" linkType="Company"&gt;Quay Pharmaceuticals&lt;/ulink&gt; in Australia,  which was acquired by Cellegy in June 2000, for the treatment of anal fissures [&lt;ulink linkID="371267" linkType="Reference"&gt;371267&lt;/ulink&gt;]. Cellegesic was approved and launched in Australia in the first quarter of 1999 [&lt;ulink linkID="371267" linkType="Reference"&gt;371267&lt;/ulink&gt;], [&lt;ulink linkID="389490" linkType="Reference"&gt;389490&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2000, Cellegy filed for approval of in New Zealand using the Australian registration package as the basis for filing [&lt;ulink linkID="389490" linkType="Reference"&gt;389490&lt;/ulink&gt;].    By April 2005, it had been launched in New Zealand [&lt;ulink linkID="595656" linkType="Reference"&gt;595656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, Cellegy filed for marketing approval in South Korea [&lt;ulink linkID="401053" linkType="Reference"&gt;401053&lt;/ulink&gt;].  In December 2002, Cellegy reported that Cellegesic had been approved in South Korea  [&lt;ulink linkID="474423" linkType="Reference"&gt;474423&lt;/ulink&gt;]. By April 2005, it had been launched in South Korea [&lt;ulink linkID="595656" linkType="Reference"&gt;595656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2005, it had been launched in Singapore  [&lt;ulink linkID="595656" linkType="Reference"&gt;595656&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In June 2013, a phase IV, single-group, open-label trial (&lt;ulink linkID="149784" linkType="Protocol"&gt;NCT01920074&lt;/ulink&gt;; APT-NIT_S-PRO-M_PEDKPK1_E) began in the US to assess the safety and exploratory efficacy of 0.4% nitroglycerin ointment in adolescents (aged &amp;gt;/= 12 to &amp;lt; 17 years old; expected n = 13) with moderate to severe pain due to chronic anal fissure. The primary endpoint was noncompartmental pharmacokinetic analyses. At that time, the trial was expected to complete in October 2014. In July 2014, recruitment was ongoing. However, by  May 2015, the study had been withdrawn due to enrollment challenges   [&lt;ulink linkID="1633367" linkType="Reference"&gt;1633367&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Healing of anal fissures&lt;/subtitle&gt;In August 2007, a pivotal, 246-patient, multicenter, placebo-controlled, US and non-US, APT trial for chronic anal fissure-associated pain began. The primary endpoint was relief from anal fissure pain. Results were expected in the first half of 2008 [&lt;ulink linkID="823726" linkType="Reference"&gt;823726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, Cellegy began a pivotal, 150-patient, placebo-controlled phase III trial for the treatment of pain associated with chronic anal fissures. The study was intended to confirm the significant pain reduction seen in the previous two phase III studies and to address FDA requirements. The agency had agreed to a special protocol assessment, that if prespecified trial results were achieved, it would approve the NDA. The protocol included agreement on the statistical methodology to be used for the analysis of results, a point of contention in the earlier trial. The study was to enroll 150 subjects in up to 40 sites, who were to receive one active dose or placebo. The primary endpoint was reduction in pain over a 21-day period, compared with 56 days for the previous study. To be eligible, subjects had to have a higher level of pain compared with the previous trial or have physical signs of a chronic anal fissure. By August 2003, 40 clinical sites had been recruited in the US and Europe, and 25 of 150 patients at 7 sites had been enrolled [&lt;ulink linkID="500241" linkType="reference"&gt;500241&lt;/ulink&gt;]. In November 2003, enrollment was completed. The study was over-enrolled, entering 193 subjects [&lt;ulink linkID="513106" linkType="reference"&gt;513106&lt;/ulink&gt;]. The trial was complete by the end of 2003  [&lt;ulink linkID="518599" linkType="reference"&gt;518599&lt;/ulink&gt;]. In January 2004, results from the trial were released. Cellegesic produced a significant reduction in anal fissure pain in comparison to placebo [&lt;ulink linkID="520189" linkType="reference"&gt;520189&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of Cellegy's first phase III trial using Cellegesic, for the treatment of patients suffering from a chronic anal fissure were published in September 2002. The report found that Cellegesic did not alter healing, but significantly and rapidly reduced the pain associated with chronic anal fissures. The randomized, double-blind, placebo-controlled study included 304 men and women diagnosed with a chronic anal fissure. Patients were randomized to one of eight treatment regimens (placebo, 0.1%, 0.2% or 0.4%, applied twice or three times daily) for up to 8 weeks. Improvement in pain was assessed daily using a visual analogue scale. Significant and rapid decreases in average pain intensity (p&amp;lt;0.0002), worst pain (p&amp;lt;0.0002) and pain at defecation (p&amp;lt;0.003) were reported for Cellegesic 0.4% [&lt;ulink linkID="464567" linkType="reference"&gt;464567&lt;/ulink&gt;], [&lt;ulink linkID="464623" linkType="reference"&gt;464623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, a second phase III trial was initiated to provide evidence that Cellegesic reduces the average daily pain associated with anal fissures. The trial was to involve 165 patients receiving treatment over 8 weeks. The primary and secondary endpoints were to be pain reduction and complete healing of the fissure, respectively [&lt;ulink linkID="359038" linkType="reference"&gt;359038&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Following completion of the first phase III trial of Cellegesic in the treatment of anal fissures, Cellegy met with the FDA in December 1999, and was granted permission to commence a confirmatory US phase III trial for the treatment of pain associated with anal fissures [&lt;ulink linkID="350907" linkType="reference"&gt;350907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1999, Cellegy completed patient enrollment in a phase III placebo-controlled trial to determine the optimum dose and dosing interval required for the cure of chronic anal fissure [&lt;ulink linkID="333655" linkType="reference"&gt;333655&lt;/ulink&gt;]. In the trial, held at multiple centers in the US and Europe, up to 304 patients received one of three doses of Cellegesic or placebo daily until the fissure was cured or up to a maximum administration period of 8 weeks [&lt;ulink linkID="281055" linkType="reference"&gt;281055&lt;/ulink&gt;], [&lt;ulink linkID="323386" linkType="reference"&gt;323386&lt;/ulink&gt;]. Cellegy unblinded the trial and announced preliminary results in November 1999. The primary endpoint of the trial (complete healing) was not met. Although 44% of the patients treated with Cellegesic experienced a complete resolution of their condition, a similar proportion treated with placebo were also cured. Nevertheless, the rate of decrease in average pain following treatment with Cellegesic was significantly greater than placebo [&lt;ulink linkID="359038" linkType="reference"&gt;359038&lt;/ulink&gt;], [&lt;ulink linkID="348226" linkType="reference"&gt;348226&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;At the end of 1998, Cellegy expected to launch Cellegesic for the treatment of anal fissures by early 2001 [&lt;ulink linkID="343762" linkType="reference"&gt;343762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Healing of hemorrhoids&lt;/subtitle&gt;In March 2005, clinical data on the use of the drug for the treatment of symptomatic chronic hemorrhoids were presented at the 10th Congress of the Asian Federation of Coloproctology in Singapore. A total of 47 patients with first- and second-degree symptomatic chronic hemorrhoids and above-normal anal sphincter pressure received Rectogesic three times per day for 2 weeks followed by 2 weeks of observation. Mean anal sphincter pressure was decreased 30 min after the first dose. Patients also had significant improvement in pain, bleeding, throbbing, itching, irritation and difficulty with bowel movement. Symptomatic improvement increased with time, even after the cessation of treatment. The drug was well tolerated; 23 patients had drug-related adverse events (19 had headaches, 3 dizziness and 1 vomiting), four of whom withdrew because of severe headaches [&lt;ulink linkID="591820" linkType="Reference"&gt;591820&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II study of Cellegesic in the treatment of hemorrhoids was ongoing in January 2001 [&lt;ulink linkID="396628" linkType="reference"&gt;396628&lt;/ulink&gt;]. The trial was scheduled to take place in three European countries and enroll patients with hemorrhoids graded on a scale of 1 to 3 [&lt;ulink linkID="354242" linkType="reference"&gt;354242&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 1998, clinical studies on over 400 patients had shown that nitroglycerin appeared to effectively heal anal fissures and hemorrhoids and is capable of rapidly relieving the pain associated with these conditions [&lt;ulink linkID="274032" linkType="reference"&gt;274032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain associated with hemorrhoidectomy&lt;/subtitle&gt;In April 1999, Cellegy commenced enrollment of patients in a phase II trial in the US to measure the use of Cellegesic in reducing the pain associated with hemorrhoid surgery [&lt;ulink linkID="322363" linkType="reference"&gt;322363&lt;/ulink&gt;]. In January 2000, following the finding that Cellegesic significantly reduced the pain of anal fissures, the trial was accelerated and expanded to include the UK [&lt;ulink linkID="352992" linkType="reference"&gt;352992&lt;/ulink&gt;]. The results of these studies were presented in June 2000 at the annual meeting of the American Society of Colon and Rectal Surgeons in Boston, MA. The study found that Cellegesic reduced the need for oral narcotics during the recovery period after hemorrhoidectomy [&lt;ulink linkID="372365" linkType="reference"&gt;372365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Female sexual dysfunction&lt;/subtitle&gt;By October 2004, Cellegesic was in phase I/II trial for dyspareunia in Australia [&lt;ulink linkID="563590" linkType="Reference"&gt;563590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, Cellegy disclosed that it was planning to include female sexual dysfunction to the list of indications pursued for Cellegesic. The company based its decision partly on favorable clinical data from a study examining the effect of nitroglycerin in the reduction of genital pain in women with vulvodynia [&lt;ulink linkID="426980" linkType="reference"&gt;426980&lt;/ulink&gt;]. In August 2002, the company published data from a study of 34 women diagnosed with vulvodynia. Topical treatment with Cellegesic was initiated in the clinic and was continued at home for 4 to 6 weeks. Patients were instructed to use topical Cellegesic, 5 to 10 minutes before sexual relations and, as part of the study, patients completed pre- and post-treatment questionnaires. An improvement in pain was reported by 91.5% of patients. Significant decreases in pain intensity and frequency of overall pain were also reported. The most common side effect was headache [&lt;ulink linkID="462213" linkType="reference"&gt;462213&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2007, Kyowa Kirin and NovaQuest  (the strategic partnering group of &lt;ulink linkID="DOL1000591" linkType="Company"&gt;Quintiles Transnational Corporation&lt;/ulink&gt;)  entered into a commercialization agreement for Kyowa Kirin's products in the US. NovaQuest received warrants for Kyowa Kirin's ordinary shares, representing a 10% premium over the last 30 days average price, exercisable over 10 years.  At that time, the drug was undergoing US trials for FDA approval  [&lt;ulink linkID="841976" linkType="Reference"&gt;841976&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nitroglycerin is an established compound for the treatment of certain cardiovascular diseases [&lt;ulink linkID="352992" linkType="reference"&gt;352992&lt;/ulink&gt;]. In March 2002, the trade name Anogesic was changed to Cellegesic, in response to the FDA's suggestion that the original name could potentially create confusion on the part of medical professionals and consumers when compared with an existing marketed product [&lt;ulink linkID="442972" linkType="reference"&gt;442972&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-07T00:00:00.000Z</StatusDate><Source id="1412517" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="1351447" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="1351447" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27664">Orexo AB</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-11-01T00:00:00.000Z</StatusDate><Source id="1458617" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22872">Aptalis Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-22T00:00:00.000Z</StatusDate><Source id="1272428" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27477">Paladin Labs Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-13T00:00:00.000Z</StatusDate><Source id="1161034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-20T00:00:00.000Z</StatusDate><Source id="1386594" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-18T00:00:00.000Z</StatusDate><Source id="595656" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-05T00:00:00.000Z</StatusDate><Source id="811092" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-18T00:00:00.000Z</StatusDate><Source id="595656" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-18T00:00:00.000Z</StatusDate><Source id="595656" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1043484">Epsilon Pharmaceuticals</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-11T00:00:00.000Z</StatusDate><Source id="661321" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-11-01T00:00:00.000Z</StatusDate><Source id="1458617" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27664">Orexo AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817965" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010792">Kyowa Kirin</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-30T00:00:00.000Z</StatusDate><Source id="604479" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27477">Paladin Labs Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="147">Hemorrhoids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2694">Dyspareunia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23168">Neptune Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-01-09T00:00:00.000Z</StatusDate><Source id="274032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23168">Neptune Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="147">Hemorrhoids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-01-09T00:00:00.000Z</StatusDate><Source id="274032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-29T00:00:00.000Z</StatusDate><Source id="747196" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-13T00:00:00.000Z</StatusDate><Source id="1161034" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-29T00:00:00.000Z</StatusDate><Source id="747196" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-29T00:00:00.000Z</StatusDate><Source id="747196" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-11T00:00:00.000Z</StatusDate><Source id="661321" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-22T00:00:00.000Z</StatusDate><Source id="1202314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><Source id="426980" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-06-28T00:00:00.000Z</StatusDate><Source id="413649" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-01-21T00:00:00.000Z</StatusDate><Source id="352992" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-05-01T00:00:00.000Z</StatusDate><Source id="322363" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-01-09T00:00:00.000Z</StatusDate><Source id="274032" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="147">Hemorrhoids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-01-09T00:00:00.000Z</StatusDate><Source id="274032" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-05-01T00:00:00.000Z</StatusDate><Source id="323386" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-18T00:00:00.000Z</StatusDate><Source id="1100921" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-16T00:00:00.000Z</StatusDate><Source id="371267" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2694">Dyspareunia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-26T00:00:00.000Z</StatusDate><Source id="563590" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27477">Paladin Labs Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-13T00:00:00.000Z</StatusDate><Source id="1161034" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-25T00:00:00.000Z</StatusDate><Source id="444619" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-06T00:00:00.000Z</StatusDate><Source id="421078" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-01T00:00:00.000Z</StatusDate><Source id="474423" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-01T00:00:00.000Z</StatusDate><Source id="389490" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575500" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575500" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-05-01T00:00:00.000Z</StatusDate><Source id="323386" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-08-22T00:00:00.000Z</StatusDate><Source id="462213" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-13T00:00:00.000Z</StatusDate><Source id="558818" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-23T00:00:00.000Z</StatusDate><Source id="657685" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-23T00:00:00.000Z</StatusDate><Source id="657685" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-08T00:00:00.000Z</StatusDate><Source id="563590" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22209">Adamis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="147">Hemorrhoids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-10-04T00:00:00.000Z</StatusDate><Source id="384638" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-01T00:00:00.000Z</StatusDate><Source id="1087030" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010792">Kyowa Kirin</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3648">Anus pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-29T00:00:00.000Z</StatusDate><Source id="747196" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1037687">Kirin Holdings Co Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1043484">Epsilon Pharmaceuticals</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1043485">New Harbor Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1043486">Ventiv Health Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1089706">Endo International plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1091305">Perrigo Co plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22209">Adamis Pharmaceuticals Corp</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>8</CountTotal></Company><Company><Company id="23066">Phytera Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]</Smiles></StructureSmiles><Deals><Deal id="107218" title="ProStrakan to market Cellegy's Tostrex and Rectogesic worldwide "></Deal><Deal id="107525" title="ProStrakan to commercialize Cellegy Pharmaceuticals' Cellegesic worldwide "></Deal><Deal id="109990" title="Orexo and ProStrakan form marketing alliance for Nordic territories for various products      "></Deal><Deal id="110389" title="Cellegy to develop Neptune's Cellegesic for hemorrhoids and anal fissures "></Deal><Deal id="117600" title="Agis to distribute Rectogesic in Israel for Cellegy    "></Deal><Deal id="117603" title="Epsilon to market Cellegy's Cellegesic for pain and anal fissure in Australia and certain Far East markets     "></Deal><Deal id="117604" title="Cellegy to license rights in China to a nitric oxide-donating product against anal fissures to New Harbor "></Deal><Deal id="117611" title="Ventiv Health to provide sales and marketing services of Cellegy's Cellegesic in the US  "></Deal><Deal id="118960" title="Paladin to market Abstral and Sancuso in Canada from Prostrakan"></Deal><Deal id="130503" title="NIH to award Cellegy funding to investigate novel therapeutics for anorectal disorders    "></Deal><Deal id="137611" title="Aptalis to commercialize ProStrakan's Rectiv for moderate to severe pain associated with chronic anal fissure in the US"></Deal></Deals><PatentFamilies><PatentFamily id="1426855" number="WO-09532715" title="Nitric oxide donor composition and method for treatment of anal disorders."></PatentFamily><PatentFamily id="1608889" number="WO-09822090" title="Treatment Of Equine Laminitis"></PatentFamily><PatentFamily id="1677946" number="WO-00143735" title="Nitroglycerin ointment for treatment of pain associated with anal disease"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mortar &amp; Pestle Veterinary Pharmacy Inc" id="1010409"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adamis Pharmaceuticals Corp" id="22209"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Falk Pharma GmbH" id="22542"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Phytera Inc" id="23066"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Norgine BV" id="28724"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>